Hepatic Impairment and Renal Impairment Study of SIM0417 Combined With Ritonavir
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, nonrandomized, open-label, parallel controlled Phase I clinical study
to evaluate the Pharmacokinetics, Safety and Tolerability of SIM0417 combined with ritonavir
after a single dose in subjects with mild and moderate renal impairment, moderate hepatic
impairment, normal renal function, and normal hepatic function. It is divided into Part A
(subjects with mild/moderate renal impairment and subjects with normal renal function) and
Part B (subjects with moderate hepatic impairment and subjects with normal hepatic function).